Abstract
The major risk factor for developing hepatocellular carcinoma (HCC) is chronic liver disease, with hepatitis C virus (HCV) and alcohol-related liver disease (ARLD) predominating historically in the United States.1 However, with the recent availability of safe and effective direct-acting antiviral (DAA) therapy for HCV, and the continuing rise in nonalcoholic steatohepatitis (NASH), the relative etiology of HCC could further evolve.1–4 In 2016, ARLD and NASH surpassed HCV as the leading indication for liver transplant (LT) in patients without HCC; similar trends may be expected for HCC LT downstream.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Paper Title
Journal
Date
